MacroGenics Discontinues Development of Vobra Duo ADC After Phase 2 Prostate Cancer Trial Results

MacroGenics has decided to stop internal development of vobramitamab duocarmazine (vobra duo), an antibody-drug conjugate targeting B7-H3, after reviewing Phase 2 data in metastatic castration-resistant prostate cancer (mCRPC)15.
The TAMARACK Phase 2 study showed median radiographic progression-free survival (rPFS) of 9.5 months for the 2.0 mg/kg dose and 10.0 months for the 2.7 mg/kg dose111.
While these efficacy results were numerically better than some existing treatments, safety concerns and an assessment of the competitive landscape led MacroGenics to discontinue further internal development15.
MacroGenics will explore potential partnering opportunities for vobra duo but will not invest additional resources into the program internally111.
The company continues to believe in B7-H3 as a target and is advancing an alternate B7-H3 ADC called MGC02615.
This decision follows previous pauses in development and safety concerns, including patient deaths reported in May 20249.

Sources:

1. https://www.fiercebiotech.com/biotech/macrogenics-pulls-plug-vobra-duo-adc-after-seeing-phase-2-prostate-cancer-data

5. https://www.fiercebiotech.com/biotech/abbvie-ends-stay-adam-family-dropping-macrogenics-partnered-adc-light-early-data

9. https://www.fiercebiotech.com/biotech/macrogenics-pauses-work-vobra-duo-adc-pending-mature-survival-data

11. https://ir.macrogenics.com/news-releases/news-release-details/macrogenics-provides-update-corporate-progress-and-2024